5-氨基-2-(N,N-二苄基氨基)-3-羟基-1,6-二苯基己烷的合成研究

目的研究5-氨基-2-(N,N-二苄基氨基)-3-羟基-1,6-二苯基己烷的合成方法.方法以L-苯丙氨酸为原料经苄基氯保护,分别与乙腈和苄基氯格氏试剂反应,再经还原得到目标化合物.结果与讨论以L-苯丙氨酸计算,总收率为34%.     

(S)-4-(4-氨基苄基)-2-(口恶)唑烷酮的合成

目的:改进(S)二4-(4-氨基苄基)-2-(口恶)唑烷酮的制备方法.方法:以L-苯丙氨酸为原料,经过硝化、酯化、还原(酯)、还原(硝基)和环合共五步反应合成抗偏头痛药物佐米曲普坦的重要中间体(S)-4-(4-氨基苄基)-2-(口恶)唑烷酮.结果:目标产物经熔点测定、1HNMR及MS-EI确证其化学结构,总收率为39.3%.结论:改进后的工艺,反应条件温和,操作简便,对环境污染较少.     

氟马西尼的有关物质B的合成(英文)

我们以7-甲氧基-4-甲基-3H-1,4-苯并二氮杂卓-2,5-(1H,4H)–二酮为原料,经脱甲基、苄基保护、环合和脱苄基反应合成了氟马西尼有关物质B。氟马西尼有关物质B结构经氢谱、碳谱和高分辨质谱确证,总收率为29.3%。该发现有助于合成工艺的优化和氟马西尼的质量控制。     

(3aR,6aS)-1,3-二苄基四氢-4H-呋喃并[3,4-d]咪唑-2,4(1H)-二酮的催化氧化工艺研究

目的研究1,3-二苄基四氢-4H-呋喃并[3,4-d]咪唑-2,4(1H)-二酮的转化利用及合成工艺。方法以1,3-二苄基四氢-4H-呋喃并[3,4-d]咪唑-2,4(1H)-二酮为原料,经醇解、TEMPO催化氧化和水解制得顺-1,3-二苄基-2-氧代咪唑-4,5-二羧酸。结果与结论目标产物结构经~1H-NMR和ESI-MS谱确证,总收率为77%(以原料计)。改进后的制备工艺具有反应条件温和、操作简便、收率高、成本低、环境友好的特点,适合于工业化生产。     

枸橼酸托法替尼的合成工艺改进

目的改进Janus激酶抑制剂枸橼酸托法替尼的合成工艺。方法以3-氨基-4-甲基吡啶为原料,经与碳酸二甲酯反应、LiAlH_4还原、与溴苄反应、NaBH_4还原再成盐酸盐,最后用L-二对甲基苯甲酰酒石酸(L-DTTA)拆分得到(3R,4R)-(1-苄基-4-甲基哌啶-3-基)甲胺-L-二对甲苯甲酰酒石酸盐(1);以4-氯-7H-吡咯并[2,3-d]嘧啶为原料,先经Ts保护,再与中间体1经亲核取代、脱Ts保护、脱苄基保护,最后与氰基乙酸缩合再与枸橼酸成盐制得枸橼酸托法替尼。结果与结论该工艺路线实现了无氢气参与的枸橼酸托法替尼的合成,优化后的工艺路线更易于大量制备,总收率为16.9%(以3-氨基-4-甲基吡啶计)。     

新型糖尿病治疗药罗格列酮的合成

以2－氯吡啶为起始原料,先合成4－[2-(甲基－2－吡啶氨基）乙氧基]苯甲醛,然后与2,4－噻唑烷二酮缩合,氢化制得罗格列酮,并对反应条件进行了优化,以2－氯吡啶计总收率为36．2％,实验结果表明：该路线具有原料易得,收率高等优点,适合工业化生产。     

4-(4-甲氧基苄基氧基)苯丙二酸-4-甲氧基苄基单酯的工艺改进

目的 4-(4-甲氧基苄基氧基)苯丙二酸-4-甲氧基苄基单酯的合成工艺改进。方法 以对甲氧基苄醇与盐酸反应后生成的对甲氧基苄氯和对羟基苯乙酸为原料,经过酯化和醚化反应及羧基的α位发生羧基化反应得到4-(4-甲氧基苄基氧基)苯丙二酸-4-甲氧基苄基单酯。结果 目标产物的结构经过熔点,1H-NMR确认。结论 与原工艺相比,改进后的工艺减少了碘化钠的用量,提高了溶剂利用率,收率高,成本低,操作简单。     

(1-苯乙基哌啶-4-基)苯胺的制备

(1-苯乙基哌啶-4-基)苯胺(1)是合成阿片类镇痛药芬太尼(fentanyl)的重要中间体[1,2].文献[3]以β-苯乙胺和丙烯酸甲(乙)酯为原料,经Michael加成、Dieckmann缩合及酸性水解得N-苯乙基-4-哌啶酮(4),再与苯胺反应生成亚胺后由四氢锂铝还原得到1,总收率为30.5％～37.5％.4也可经三乙酰氧基硼氢化钠还原氨化[4]得到1.本研究改用雷尼镍催化下还原氨化,收率89.5％.改进后的总收率可提高至77.7％,且成本降低.1的合成路线见图1.     

1-(4-吡啶基)-2-丙酮的新合成方法

报道了以4甲基吡啶为原料,经酰化和相转移催化水解反应制备强心药物米利酮关键中间体1(4吡啶基)2丙酮的新合成方法,总收率达731%.     

莫西沙星的合成

以吡啶-2,3-二羧酸为原料,依次经脱水、氨解、环合、还原吡啶环及羰基、拆分和氢解脱苄基得(S,S)-八氢-6H-吡咯并[3,4-b]吡啶后,与1-环丙基-6,7-二氟-1,4-二氢-8-甲氧基-4-氧代喹啉-3-羧酸根-硼-二乙酸酐缩合并水解去螯合得到莫西沙星.总收率43.3%.     

诺美孕酮乙酸酯3—（O—羧甲基）肟的合成及其异构体的分离

诺美孕酮乙酸酯与羧甲氧基胺半盐酸盐在含少量吡啶的甲醇中室温反应,反－诺美孕酮乙酸酯３－（Ｏ－羧甲基）肟的两种立体异构体的混合物。经层析分离以２：１的比例得到两种立体异构体。     

Synthesis and pharmacological activities of 2-(3'-substituted-2'-hydroxypropylamino)pyridines

In the present study, a series of 2-(3'-substituted-2'-hydroxypropylamino)pyridines were synthesized and characterized by IR, 1H-NMR and elemental analysis. The compounds were investigated for anticonvulsant (150, 300 mg/kg) and cardiac activity. 2-(3'-Diethylamino-2'-hydroxypropylamino)pyridine 3 was found to exhibit the highest anticonvulsant activity. 2-(3'-Dimethylamino-2'-hydroxypropylamino)pyridine 2 and 2-[3'-(4'-nitrophenylamino)-2'-hydroxypropylamino]pyridine 6 were found to exhibit negative ionotropic activity. 2-(3'-Dimethylamino-2'-hydroxypropylamino)pyridine 2, 2-[3'-(4'-nitrophenylamino)-2'-hydroxypropylamino]pyridine 6 and 2-(3'-piperidino-2'-hydroxypropylamino)pyridine 8 were found to antagonize exhibit beta-adrenergic activity.     

Formation of water-soluble pincer silver(I)-carbene complexes: a novel antimicrobial agent

Silver(I)-2,6-bis(ethanolimidazolemethyl)pyridine hydroxide (4a) and silver(I)-2,6-bis(propanolimidazolemethyl)pyridine hydroxide (4b) are water-soluble silver(I)-carbene complexes that were synthesized in high yield by reacting silver(I) oxide with N-substituted pincer ligands 3 (a = 2,6-bis(ethanolimidazoliummethyl)pyridine diiodide, b = 2,6-bis(propanolimidazoliummethylpyridine)pyridine dibromide). The X-ray crystal structure of 4a is a one-dimensional linear polymer, whereas the mass spectroscopy confirms a monomer in the gas phase. A change in the anion of 4a from a hydroxide to a hexafluorophosphate formed a silver(I)-carbene complex 4c that is dimeric in structure and insoluble in water. The bactericidal activities of the water-soluble silver(I)-carbene complexes were found to be improved over that of silver nitrate.     

Synthese von substituierten Bis-(p-hydroxyphenyl)-pyridyl-(2′)-methanen

Synthesis of Substituted 2-[Bis(4-hydroxyphenyl)methyl]pyridines 2-[Bis(4-hydroxyphenyl)methyl]pyridines substituted at the pyridine nucleus were prepared from the corresponding heterocyclic aldehydes.     

Potential anti-inflammatory agents II. 7-Methyl-s-triazo(4,3-a)pyridines]

A synthesis of eight derivatives of 7-methyl-s-triazo-[4,3-a]pyridine substituted in position 3, has been made with a view to studying their possible antiinflammatory and analgesic action. Among the obtained compounds only the 3-(alpha-hydroxyethyl)-7-methyl-s-triazo[4,3-a]pyridine presents an activity similar to aspirin.     

2,4,6-三(1H-苯并咪唑-2-基)吡啶和2,4,6-三(1H-咪唑并[4,5-c]吡啶-2-基)吡啶的微波辐射合成

苯并咪唑类衍生物及其金属配合物具有良好的生物活性,可用作抗寄生虫药和质子泵抑制剂等。近年来的药理研究证明,此类化合物对肝炎、骨炎、脾炎等也具有治疗和预防作用,还可作为有机合成反应的中间体。三苯并咪唑类和三吡啶并咪唑类化合物亦具有类似的生理活性。     

Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist

In this study, the piperidine ring of immepip and its analogues was replaced by a rigid heterocyclic pyridine ring. Many compounds in the series exhibit high affinity and agonist activity at the human histamine H(3) receptor. Particularly, the 4-pyridinyl analogue of immepip (1c, immethridine) is identified as a novel potent and highly selective histamine H(3) receptor agonist (pK(i) = 9.07, pEC(50) = 9.74) with a 300-fold selectivity over the closely related H(4) receptor.     

Dehydrative metabolites of 1-(3-chlorophenyl)-1methyl-2-phenyl-2-(2-pyridine)ethanol as potential hypocholesteremic agents

The E and Z isomers of 2-[2-(3-chlorophenyl)-1-phenyl-1-propenyl]pyridine (2a,b) and 2-[2-(3-chlorophenyl)-1-(4-hydroxyphenyl)-1-propenyl]pyridine (4a,b) were synthesized and separated as possible metabolites of 1-(3-chlorophenyl)-1-methyl-2-phenyl-2-(2-pyridine)ethanol (1a). Following administration of 1a to rats, a HPLC system was used to examine urine and serum specimens for the less polar metabolites of 1a. Isomers 2a and 2b were not detected but their hydroxylated derivatives 4a and 4b were observed as minor metabolites. Compounds 2a,b and 4a,b exhibited hypocholesteremic activity in rats; compounds 4a and 4b are of special interest because they possessed relatively low estrogenicity.     

Interferon inducing activities of derivatives of 1,3-dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo(3,4-b)quinoline and related compounds.

Syntheses and interferon inducing acitivites are reported for 137 relatives of 1,3-dimethyl-4-(3-dimethylamino-propylamino)-1H-pyrazolo[3,4-b]quinoline (1). Three different generalized synthetic schemes for the preparation of pyrazolo[3,4-b]quinolines are presented and limitations contrasted. Other heterocyclic nuclei containing the 3-dimethylaminopropylamino side chain include pyridine, quinoline, acridine, pyrazolo[3,4-b]pyridine, pyrazolo[3,4-B][1,8]naphthyridine, pyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidine, dipyrazolo[3,4-b:4',3'-e]pyridine, pyrrolo-[2,3-b]quinoline, isothiazolo[5,4-b]quinoline, and pyrido[2,3-h]pyrazolo[3,4-b]quinoline. Structural requirements for interferon induction in this series are discussed and two of the more active compounds (172 and 196) are compared directly with tilorone.     

Bequeme Synthese von Bis-3′-0-(5-ethyl-2′-desoxyuridin)-sulfoxid (KK-Ro 258)

Convenient Synthesis of Bis-3′-0-(5-ethyl-2′-deoxyuridine) Sulfoxide (KK-Ro 258) The title compound 4 was prepared by treating 5′-0-trityl-5-ethyl-2′-deoxyuridine with thionyl chloride in a mixture of dichloromethane and pyridine. The trityl group was removed by standard procedures.